Brief: Vertex And Ono Pharmaceutical Announce Strategic Agreement To Develop & Commercialize Povetacicept In Japan & South Korea
23/06/2025 10:39
June 23 (Reuters) - Vertex Pharmaceuticals: VERTEX AND ONO PHARMACEUTICAL ANNOUNCE STRATEGIC AGREEMENT TO DEVELOP AND COMMERCIALIZE POVETACICEPT IN JAPAN AND SOUTH KOREA VERTEX PHARMACEUTICALS: WILL RECEIVE AN UPFRONT PAYMENT, AS WELL AS CERTAIN REGULATORY AND COMMERCIAL MILESTONE PAYMENTS AND TIERED ROYALTIES Source text: ID:nBwm1mnca Further company coverage: 4528.T ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Vertex Pharmaceuticals
See all newsBrief: Vertex Announces US FDA Acceptance Of Biologics License Application For Accelerated Approval Of Povetacicept In IgA Nephropathy
U.S. RESEARCH ROUNDUP- CAVA Group, Eagle Materials, Vertiv Holdings
Vertex Q1 adjusted EPS beats estimates, revenue rises 8%
Vertex tops profit estimates as sales of new cystic fibrosis drug surge
Brief: Vertex Pharmaceuticals Q1 Adjusted EPS USD 4.47 Vs. IBES Estimate USD 4.31